Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Intellia Therapeutics Inc
NASDAQ:NTLA
$20.44
Open 19.19 Prev Close 18.76
High 20.58 Low 18.92
Volume 7,816,326 Volume (Avg) 5,236
52 Week High 21.47 52 Week Low 5.90
Market Cap 2.2B PE Ratio

General

NameIntellia Therapeutics Inc
TickerNTLA
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
CountryUSA
Fiscal Year EndDecember
Full Time Employees403

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Highlights

Analyst Target34.09
Market Cap2,194,200,000
PEG Ratio-0.10
EBITDA-501,873,984

Valuation

Price/Sales (Trailing 12 Mt.)38.10
Price/Book (Most Recent Quarter)2.45

Technicals

Beta2.46
52 Week High21.47
52 Week Low5.90
50 Day Average59.88%
200 Day Average95.64%

Earnings

Most Popular

Donald Trump's Approval Rating Crashes to Record Low — Here's What's Driving the Decline

According to the recent YouGov/Economist poll, President Trump's approval rating has taken a nosedive, reaching its lowest point in his second term.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Cathie Wood Loads Up On Bullish Inc, Pony AI And Robinhood — Dumps Kratos Defense Amid Taiwan Drone Buzz

On Sept 17, 2025, Cathie Wood-led Ark Invest executed significant trades involving Bullish, Kratos Defense, Pony AI, and Robinhood. These reflect Ark's focus on emerging tech and defense sectors.

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure (CHF), chro

Why This Crypto Skeptic Had a Change of Heart - Ad

He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.

Carney Cuts The Red Tape, Unveils Over $43 Billion In Flagship Projects

PM Mark Carney announces first projects to be reviewed by Canada's new Major Projects Office, aiming to cut red tape and attract investments.

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

Kimmel's suspension is the latest display of Trump's growing power over the US media landscape

WASHINGTON (AP) — has used threats, lawsuits and government pressure as he remakes the American media landscape, unleashing his long-standing grievances against an industry that has mocked, criticized and scorned him for years.

Time to Say Goodbye to "Old" Dollar? Say Hello to "Trump's New Dollar" - Ad

If you have any money in U.S. dollars... learn how to prepare for "Trump's new dollar"... Because this could be the biggest change to our financial system in 54 years. President Trump even called it: "The greatest revolution in financial technology since the birth of the internet itself."

Ex-Trump Lawyer Raises Alarms: 'I Have Never Been As Concerned As To Whether Our System Can Withstand The Pressure'

Abbe Lowell, a lawyer who once represented President Donald Trump's family, has expressed grave concerns over the potential harm the current administration could cause to the country's institutions.

New England's shrimp industry is struggling, with fishermen catching few in 2025

PORTLAND, Maine (AP) — There's an effort underway to bring New England shrimp back to seafood customers — but fishermen have found few of the crustaceans, and the fishing industry that harvests them may face an even longer shutdown.

[Revealed] Trump's Next AI Executive Orders? - Ad

A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.

AI Bull Market Fuels A Wave Of New Listings: 3 IPO ETFs In Focus

IPO-ETFs like IPO, FPX and FPXI are in focus as the U.S. market sees its fastest rebound since 2021, fueled by the AI boom and $23B raised year-to-date.

Trump reveals Murdochs and Dell could potentially take part in TikTok deal

President Donald Trump said prominent billionaires – including media mogul Rupert Murdoch and tech founder Michael Dell – could be part of a deal in which the U.S. will take control of the .

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Google's top AI scientist says ‘learning how to learn’ will be next generation's most needed skill

ATHENS, Greece (AP) — A top Google scientist and 2024 Nobel laureate said Friday that the most important skill for the next generation will be “learning how to learn” to keep pace with change as transforms education and the workplace.

Gold Is Being Reintroduced Into the Monetary System - Ad

While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.

Utah Governor After Kirk Killing: 'Social Media Is A Cancer On Our Society Right Now'

Utah Gov. Spencer Cox urged unity after Charlie Kirk's killing, warning that "social media is a cancer on our society right now."

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Here's How Much $1000 Invested In Union Pacific 20 Years Ago Would Be Worth Today

Union Pacific (NYSE: UNP) has outperformed the market over the past 20 years by 4.88% on an annualized basis producing an average annual return of 13.7%. Currently, Union Pacific has a market capitalization of $138.27 billion.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

From Wall Street To Web3: Carbon Markets Move On-chain

Tokenization could boost transparency, reduce fraud, and increase liquidity in carbon markets.

Big Tech's energy-hungry data centers could be bumped off grids during power emergencies

HARRISBURG, Pa. (AP) — With the explosive growth of Big Tech's data centers threatening to overload U.S. electricity grids, policymakers are taking a hard look at a tough-love solution: bumping the energy-hungry data centers off grids during power emergencies.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Scott Bessent Meets BlackRock's Rick Rieder As Trump Eyes Fed Chair Replacement For Jerome Powell: Report

Scott Bessent is interviewing candidates to replace Jerome Powell as Federal Reserve Chair by May 2026, with BlackRock's Rick Rieder among those being considered.

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

MediaTek Adopts Taiwan Semiconductor 2nm Breakthrough For Flagship Chip

MediaTek partners with TSMC to develop a flagship SoC using the new 2nm process, a major leap for both companies.

Appeals court rejects Trump's bid to unseat Federal Reserve governor Lisa Cook ahead of rate vote

WASHINGTON (AP) — An appeals court ruled Monday that can remain a Federal Reserve governor, rebuffing President Donald Trump’s efforts to remove her just ahead of a key vote on interest rates.

Why This Crypto Skeptic Had a Change of Heart - Ad

He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.

US sanctions Iranian financiers, others over $100M in cryptocurrency transfers from Iran oil sales

WASHINGTON (AP) — A pair of Iranian financiers and more than a dozen people and firms across Hong Kong and the United Arab Emirates were sanctioned Tuesday for allegedly coordinating $100 million worth of cryptocurrency transfers from the sale of Iranian oil for the benefit of Iran's government and military.

Most Recent

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright priceactionea.net
Privacy Policy | Terms of Service